Shared from twixb · statnews.com
Marty Makary has officially resigned as FDA commissioner, with Kyle Diamantas appointed as the acting commissioner, as confirmed by President Trump.
The content does not provide a relevant insight for someone focused on healthtech, biotech, or related fields since it primarily reports on a change in FDA leadership without discussing direct implications for biotech or healthtech sectors.
Powered by twixb
twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.
Recent stories curated alongside this one.
Owkin has signed a three-year licensing agreement with AstraZeneca for its AI Scientist platform, K Pro, which is aimed at enhancing pharmaceutical research and decision-making.
Abeona Therapeutics has shifted its focus from eye gene therapies to developing solid tumor T cell therapies, while also providing updates on companies including Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech, and C4 Therapeutics.
Icon, a global contract research organization, has opened a new research facility in San Antonio, Texas, and established satellite clinics in Houston and Lawrence, Kansas, to enhance its clinical trial capabilities.
WHOOP has introduced new AI features, including on-demand video consultations with licensed medical clinicians for U.S. users and EHR syncing through a partnership with HealthEx.
A new series has been launched investigating the alcohol epidemic in the U.S., focusing on industry influences and treatment gaps. Additionally, Rigel Pharma has partnered with Arvinas and Pfizer to market a new breast cancer drug, Roche has received European clearance for an early Alzheimer's blood test, and BridgeBio has submitted an FDA application for a drug to treat a rare genetic disease.
